Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D

Clinical trial NCT03099785 · COMPLETED

Trial details

NCT number: NCT03099785
Sponsor: Cosmo Technologies Ltd
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Diarrhea-predominant Irritable Bowel Syndrome

Start date: 2017-12-18
Primary completion: 2020-09-11
Enrollment: 279

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.